Share on StockTwits

Alexion Pharmaceuticals (NASDAQ:ALXN) has received an average recommendation of “Buy” from the eighteen analysts that are covering the company, AnalystRatings.Net reports. Five research analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $183.00.

In other Alexion Pharmaceuticals news, CEO Leonard Bell unloaded 70,000 shares of the company’s stock on the open market in a transaction that occurred on Friday, August 15th. The shares were sold at an average price of $167.99, for a total transaction of $11,759,300.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

A number of analysts have recently weighed in on ALXN shares. Analysts at Nomura reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $224.00 price target on the stock, up previously from $222.00. Separately, analysts at Stifel Nicolaus reiterated a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $222.00 price target on the stock, up previously from $220.00. Finally, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Alexion Pharmaceuticals in a research note on Friday, July 25th. They now have a $220.00 price target on the stock, up previously from $210.00.

Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) opened at 168.22 on Thursday. Alexion Pharmaceuticals has a 1-year low of $100.89 and a 1-year high of $185.43. The stock’s 50-day moving average is $163.3 and its 200-day moving average is $162.9. The company has a market cap of $33.276 billion and a price-to-earnings ratio of 83.44.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, July 24th. The company reported $1.12 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.07 by $0.05. The company had revenue of $512.50 million for the quarter, compared to the consensus estimate of $509.54 million. During the same quarter last year, the company posted $0.73 earnings per share. Alexion Pharmaceuticals’s revenue was up 38.5% compared to the same quarter last year. On average, analysts predict that Alexion Pharmaceuticals will post $5.01 earnings per share for the current fiscal year.

Alexion Pharmaceuticals, Inc (NASDAQ:ALXN) is a biopharmaceutical company focused on serving patients with severe and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.